Medical and revascularization management in acute coronary syndrome in rennal patients

Seminars in Nephrology

Volumn 21, Issue 1, 2001, Pages 25-35

  Fernandez, Jocelyn S ^a   Sadaniantz, Ara ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANISTREPLASE; CREATINE KINASE MB; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEART ENZYME; HEPARIN; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; STREPTOKINASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DIAGNOSTIC PROCEDURE; DOSE KIDNEY FUNCTION RELATION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG METABOLISM; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING;

EID: 0035135231     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2001.18372     Document Type: Article

References (70)

1. Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease
2. Lipoprotein(a) as a risk factor for coronary disease in hemodialysis patients
3. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy
4. Natural history of asymptomatic coronary angiographic lesions in diabetic patients with end-stage renal disease
5. Onset of coronary artery disease prior to initiation of hemodialysis in patients with end-stage renal disease
6. New perspectives on coronary artery disease in hemodialysis patients
7. Coronary revascularization in insulin-dependent diabetic patients with chronic renal failure
8. Dialysis-associated ischemic heart disease: Insights from coronary angiography
9. Painless myocardial ischemia in chronic hemodialysed patients. A real event?
10. Incidence of arrhythmias and myocardial ischemia during hemodialysis and hemofiltration
11. Incidence of long-term significance of transient ST segment deviation in hemodialysis patients
12. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction
13. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure
14. Monocyte expression of tissue factor and adhesion molecules: The link with accelerated coronary artery disease in patients with chronic renal failure
15. Use of dobutamine echocardiography for cardiac risk stratification of patients with chronic renal failure
16. Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates
17. Value of thallium myocardial imaging in the prediction of future cardiovascular events in patients with end-stage renal failure
18. Unmasking artifactual increases in creatine kinase isoenzymes in patients with renal failure
19. Reliability and significance of increased creatine kinase MB isoenzyme in the serum of uremic patients
20. Creatine kinase sub-form analysis in hemodialysis patients without acute coronary syndromes
21. Determinants of serum creatine kinase activity in dialysis patients
22. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure
23. Cardiac troponin T in hemodialyzed patients
24. The predictive value of cardiac troponin T measurements in subjects on regular hemodialysis
25. Cardiac troponin elevations in chronic renal failure: Prevalence and clinical significance
26. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: Evidence of cardiac troponin T expression in skeletal muscle
27. Prognostic value of serum cardiac troponin I and T in chronic dialysis patients: A 1-year outcomes analysis
28. Cardiac troponin I: A marker with high specificity for cardiac injury
29. Cardiac troponin-I accurately predicts myocardial injury in renal failure
30. Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long-term hemodialysis patients and effect of hemodialysis on these cardiac markers
31. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
32. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2
33. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction
34. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
35. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
36. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
37. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
38. Successful thrombolytic therapy for acute myocardial infarction in a renal transplant patient
39. Systemic thrombolysis for acute myocardial infarction in a renal transplant recipient
40. Long-term survival of dialysis patients receiving thrombolytic therapy for acute myocardial infarction in the United States
41. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis
42. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
43. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina
44. Low-molecular-weight heparin during instability in coronary artery disease
45. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease
46. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit
47. Low molecular weight heparin half-life is prolonged in hemodialysed patients
48. International randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
49. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
50. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
51. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
52. Bleeding time in uremia: A useful test to assess clinical bleeding
53. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb/IIIa receptors
54. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure
55. Myocardial revascularization in patients on renal replacement therapy
56. Short-and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients
57. Efficacy of percutaneous transluminal coronary angioplasty for patients on hemodialysis: Comparison with those not on dialysis
58. A comparison of coronary artery bypass grafting and percutaneous transluminai coronary angioplasty in patients on hemodialysis
59. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa inhibitor in high-risk coronary angioplasty
60. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
61. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
62. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
63. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
64. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
65. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty